Angela Consagra
YOU?
Author Swipe
View article: Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database
Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database Open
Introduction: HMA monotherapy (HMAm) continues to be the standard of care for HR-MDS. While the addition of VEN to azacitidine (AZA) improved overall survival (OS) and complete remission (CR) rates among older pts with acute myeloid leukem…
View article: How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome
How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome Open
Summary Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS…
View article: Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS Open
We explored the impact of luspatercept therapy on overall survival (OS) and possible predictors of response in low‐risk (LR) myelodysplastic syndrome (MDS) patients. We evaluated 331 anemic patients treated with luspatercept. Hematological…
View article: Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database Open
Introduction The International Prognostic Scoring System (IPSS) and its revised version (IPSS-R) were developed using datasets from patients (pts) with untreated MDS. The cytogenetic risk groups used in IPSS-R were expanded to 5 groups fro…
View article: Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features Open
Background. Recent advancements in genome characterization have transformed the study of myeloid neoplasms (MN). Accordingly, there is a shift from traditional classification schemes, based on morphological and clinical information, to nex…
View article: Exploring the Unseen Effects of Epigenetic Age Acceleration in Low-Risk MDS: Associations with Unique Cytokine Profiles
Exploring the Unseen Effects of Epigenetic Age Acceleration in Low-Risk MDS: Associations with Unique Cytokine Profiles Open
Introduction Ageing is a major risk factor for the development of Myelodysplastic Syndromes/Neoplasms (MDS). Epigenetic alterations are common in MDS, especially aberrant DNA methylation. On a different level, DNA methylation at specific g…
View article: A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML) Open
Background. Study of myeloid neoplasms (MN) has been rapidly transformed by genome characterization. Gene mutations have been reported to influence disease phenotype and risk of disease progression, and the evaluation of mutational status …
View article: Myelodysplastic Syndromes with Concomitant <i>SF3B1</i> Mutation and Deletion of the Long Arm of Chromosome 5 (<i>SF3B1</i>del5q): Outcomes and Response to Treatment
Myelodysplastic Syndromes with Concomitant <i>SF3B1</i> Mutation and Deletion of the Long Arm of Chromosome 5 (<i>SF3B1</i>del5q): Outcomes and Response to Treatment Open
Background Both MDS-SF3B1 and isolated del(5q) MDS are recognized by WHO and ICC 2022 as unique molecularly-defined MDS entities. Reports including the molecular revised international prognostic scoring system (IPSS-M) indicate that concom…
View article: Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes Open
Relevance of germline (GL) predisposition in myelodysplastic syndromes (MDSs) was stressed in both 2022 WHO and International Consensus classifications, but its incidence is probably underestimated, especially in young adult patients. We s…
View article: Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine
Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine Open
Background Oral formulations ofhypomethylating agents decitabine (ASTX727) and azacitidine (cc-486, AZA) were approved respectively for treatment of higher risk myelodysplastic syndromes (HR-MDS) and for maintenance of acute myeloid leukem…
View article: Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients
Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients Open
Background. Chronic myelomonocytic leukemia (CMML) is a rare myeloid neoplasm that shares both dysplastic and proliferative features and includes patients with highly heterogeneous clinical manifestations and prognosis. Despite known co-mu…
View article: Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts Open
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts
View article: <scp><i>PIEZO1</i></scp> mutations impact on early clinical manifestations of myelodysplastic syndromes
<span><i>PIEZO1</i></span> mutations impact on early clinical manifestations of myelodysplastic syndromes Open
PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes